We formulated PA-824, a nitroimidazopyran with promise for the treatment of 2 tuberculosis, for efficient aerosol delivery to the lungs in a dry powder porous 3 particle form. The objectives of this study were to prepare and characterize a 4 particulate form of PA-824, assess the stability of this aerosol formulation at 5 different environmental conditions and determine the pharmacokinetic 6 parameters of the powder after pulmonary administration. The drug was spray 7 dried into porous particles containing a high drug load and possessing desirable 8 aerosol properties for efficient deposition in the lungs. Physical, aerodynamic 9 and chemical properties of the dry powder were stable at room temperature for 10 six months and refrigerated conditions for at least one year. Pharmacokinetic 11 parameters were determined in guinea pigs after pulmonary administration of the 12 PA-824 powder formulation at three doses (20, 40, 60 mg/kg) and compared to 13 intravenous (20 mg/kg) and oral (40 mg/kg) delivery of the drug. Oral and 14 inhaled delivery of PA-824 achieved equivalent systemic delivery at the same 15 body dose within the first twelve hours of dosing. However, animals dosed by 16 the pulmonary route showed drug loads remaining locally in the lungs 32 hours 17 post-exposure whereas those given oral drug cleared more rapidly. Therefore, 18
Introduction 24
The global epidemic caused by the infectious disease tuberculosis (TB) has 25 garnered attention recently due to the growing concern over the emergence of 26 multi-drug resistant tuberculosis (MDR-TB) and extensively drug resistant 27 tuberculosis (XDR-TB), which are caused by Mycobacterium tuberculosis that 28
show resistance to multiple first-line drugs or that are virtually untreatable by 29 existing TB antibiotics (6). An investigational nitroimidazopyran, PA-824, is one 30 of the most promising TB drug candidates in thirty years. PA-824 appears to 31 have bactericidal activity against both active replicating and persisting or latent 32
M. tuberculosis with the potential of treating MDR-TB (21). It has been proposed 33
that this activity against static bacilli could help sterilize TB lesions faster (26) . 34
Therefore, reduced treatment times may be possible with drug regimens that 35 include PA-824. Any advance in TB therapy that addresses drug resistant 36 tuberculosis and reduces frequency of dosing, dose required and duration of 37 treatment has the potential to improve patient treatment. 38
39
Preclinical evaluation in animal models of PA-824 alone and in combination with 40 moxifloxacin, rifampicin, isoniazid and/or pyrazinamide indicated potential for the 41 treatment of TB and MDR-TB (9, 13-15, 21, 22, 25) . Drugs were delivered orally 42 in these studies, with likely only a fraction of the administered dose reaching the 43 lung tissue, the primary infection site of TB. Thus, direct delivery of PA-824 to 44 the lungs could improve the effectiveness of treatment by increasing the local 45 concentration of drug in the lungs thereby targeting pulmonary TB, while still 46 The disposition of PA-824 after oral delivery was determined previously in mice 74 (10, 13), rats (20), dogs and monkeys (16), but not after pulmonary delivery to 75 guinea pigs. The TB infected guinea pig model is a clinically relevant animal 76 model with respect to human disease because the pathogenesis and lung 77 pathology in guinea pigs mimics that in humans with active TB (12, 17, 24) . It is 78 likely that drug disposition will be different in TB infected animals than in healthy 79 animals. As the initial step to determine PA-824 disposition in guinea pigs, the 80 present studies were conducted in healthy animals to define baseline 81 pharmacokinetic parameters of PA-824 after intravenous administration of 82 solution and pulmonary administration of the dry powder formulation, and 83 compared to those obtained by the oral standard route of delivery. In addition, 84 local PA-824 concentrations were determined in the lungs after the drug 85 concentration became undetectable in systemic circulation to evaluate the 86 efficiency of delivery by both routes of administration. MA) Milli-Q water purification system was used. 101
A C C E P T E D
on
102

Preparation of Porous Particles 103
The spray drying solution was prepared by dissolving L-leucine in pure water at 104 55 ºC. PA-824 and DPPC were then added to ethanol with heating and stirring. 105
The aqueous solution was added to the ethanol mixture immediately before 106 spray drying for a final solids concentration of 4 g/L and solvent ratio of 70% 107 ethanol and 30% water (v/v). The final formulation consisted of a ratio of 108 75:20:5, PA-824: L-leucine:DPPC (wt %). 109
110
Porous particles were prepared using a Niro, Inc. Mobile Minor spray dryer 111 (Columbia, MD). The inlet temperature was set at 107 ºC and the solution feed 112 rate at 60 ml/min. The solution was pumped into the two-fluid nozzle of the spray 113 dryer with a gas flow rate of 25 g/min. Spray dried powders were collected in a 114 container at the outlet of the cyclone. 115
Particle Characterization 116
Characterization of Dry Powders 117
The volume diameter of the spray dried powder was measured by laser 118 diffraction using a HELOS system with RODOS dry dispersing unit (Sympatec 119
Inc., Lawrenceville, NJ). Each measurement was performed in triplicate at an 120 applied pressure of 2 bar. 121
122
The aerodynamic properties and particle distribution of the powder (fine particle 123 fraction, FPF; mass median aerodynamic diameter, MMAD; geometric standard 124 deviation, GSD) were determined with standard methodology using an eight-125 stage Andersen Cascade Impactor (ACI; Copley Scientific Limited, Nottingham, 126 UK). The fine particle fraction of the total dose of powder less than or equal to an 127 effective cut-off aerodynamic diameter of 5.8 µm (FPF TD ) was calculated by 128 dividing the powder mass recovered from stages 1-7 of the impactor by the total 129 particle mass. 130
131
The morphology of the dry particles was evaluated using a 982 field emission 132 scanning electron microscope (SEM, LEO, Carl Zeiss, Inc., Thornwood, NY) after 133 coating powder samples with a Platinum/Palladium layer (208HR sputter coater, 134
Cressington Scientific Instruments Inc., Watford, UK). from storage at 0, 0.5, 1, 3, 6 and 12 months and allowed to equilibrate to room 159 temperature before analysis. The powders were analyzed in triplicate for particle 160 size, fine particle fraction of the total dose and drug content. Statistical 161 placed at a distance of 1 cm from the carina. PA-824 powders were dispersed 182 with the help of 5 mL of air from an empty syringe. The insufflator chamber and 183 tube containing the dose of PA-824 powder were weighed carefully before and 184 after delivery to the animal to estimate the actual delivered dose to be used for 185 the PK analysis for each animal. 186 187 PA-824 was formulated into a micelle suspension for oral dosing with 10% 188 hydroxypropyl-β-cyclodextrin and 10% lecithin as described previously (15 
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Statistical Analysis 233
Data for the pharmacokinetic study was subjected to analysis of variance 234 (ANOVA) and least-squares significant-differences multiple comparison method. 235 A probability level of 5% (p < 0.05) was considered to be statistically significant. 236
237
RESULTS
238
Particle manufacture and characterization 239
Porous particles with a load of approximately 75% (w/w) PA-824 were prepared 240 by spray drying. The resulting dry powder formulation consisted of thin-walled 241 porous particle structures as shown in Figure 1 . The median volume diameter of 242 the particles was 4.14 ± 0.04 µm, and had desirable aerosol properties for human 243 pulmonary delivery (7, 11) 
Pharmacokinetic studies 260
Average PA-824 plasma concentration versus time curves are shown in Figure 3 . 261
The terminal phases of these curves appear to be linear for all treatments. A 262 dose dependency was observed among groups receiving particles by the 263 pulmonary route, with animals receiving the largest dose having the highest 264 plasma concentration and PA-824 remaining detectable for a longer period of 265 time. Interestingly, the plasma concentration versus time profiles for animals 266 dosed by the oral and pulmonary routes with 40 mg/kg of PA-824 appeared 267 almost superimposable for the first 8 hours, but plasma concentrations in animal 268 receiving an oral dose were detectable only 12 hours after dosing, whereas those 269 of animals dosed by the pulmonary route remained detectable 24 hrs after dose 270
administration. 271 272
The local PA-824 concentrations remaining in the lungs 32 hours after drug 273 administration to the different groups are shown in Figure 4 . PA-824 was 274 detectable at levels well above the detection threshold of the analytical method 275 in the lungs of the three groups of animals dosed by the pulmonary route in a 276 dose dependent manner, whereas no drug was detected in the lungs of animals 277 receiving PA-824 by the intravenous or oral routes. 278
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on October 16, 2017 by guest http://aac.asm.org/ Downloaded from PK parameters obtained by non-compartmental methods are presented in Table  279 1. AUC and C max after PA-824 administration by the pulmonary route increased 280 linearly with the dose (R 2 = 0.999) with statistical differences between the three 281 values. AUC was statistically comparable in animals receiving 40 mg/kg by the 282 oral and pulmonary routes. However, PA-824 was eliminated (K) at a slower rate 283 when given at doses of 40 and 60 mg/kg by the pulmonary route, correlating with 284 significantly longer half-lives (t 1/2 ) and mean residence time (MRT). Notably, 285 among animals receiving 40 mg/kg PA-824, t 1/2 by the pulmonary route was 286 almost double that of those receiving the drug by the oral route. C max and T max 287
were statistically comparable in groups of animals receiving the 40 and 60 mg/kg 288 doses. Bioavailability was approximately 60% and statistically comparable in all 289 treatment groups. 290
291
DISCUSSION 292
The continuing TB epidemic, including a growing number of cases of MDR/XDR-293 TB and the increasing co-incidence of HIV and TB synergy, requires new and 294 improved treatment as part of the strategy for containment and reduction of the 295 infection. The first drug demonstrating promise in treating both active and latent 296 tuberculosis is the nitroimidazopyran PA-824, typically administered orally. Our 297 goal was to develop PA-824 in a form suitable for delivery as an aerosol directly 298 to the lungs, the primary site of TB infection. 299
We have shown the potential for the antibiotic PA-824 to be formulated into a dry 301 powder porous particle form that can be delivered efficiently by the pulmonary 302 route. This high drug load formulation maintained physical, aerodynamic and 303 chemical stability at refrigerated conditions (4 ºC) for over a year and room 304 temperature (25 ºC) for more than six months. This room temperature stability 305 may reduce the need for a cold chain for storage and distribution. At accelerated 306 conditions (40 ºC), chemical stability was maintained throughout the 12 month 307 study duration, while aerodynamic properties showed significant decline at six 308 months at this elevated temperature. This heat sensitivity is typical for dry 309 powders to be delivered by inhalation (2). In summary, the stability of the 310 formulation is temperature dependent, with chemical and physical stability 311 maintained during the 12 month study duration at refrigerated conditions and for 312 more than six months at room temperature conditions, while likely allowing for 313 short-term storage excursions at higher temperatures. 314 315 Pharmacokinetic parameters after oral administration of PA-824 in guinea pigs 316 were determined in the present study, revealing that the disposition of PA-824 317 differed from literature reports for other different species. Half-life after oral 318 administration in guinea pigs (2.43 h) was comparable to that in monkeys and 319 rats (2-5 h) (16), but slightly longer than that in dogs (1-2 h), confirming the 320 observation that systemic absorption in dogs may be low due to poor absorption 321 and rapid metabolism (16). T max after oral administration to guinea pigs (4 h) was 322 also similar to that in monkeys (3.33 h), but significantly shorter than that in rats 323 we propose that pulmonary delivery may achieve the same efficacy as oral at the 359 same body dose, with a potential improvement in effectiveness related to 360 pulmonary infection. This may translate into the ability to deliver lower body 361 doses with less frequency than standard dosing regimens. 362 insufflation showed sustained levels of PA-824 in the lungs after 32 hours. There 526 also appears to be a dose dependency on the drug levels remaining in the lungs 527 (Mean ± standard deviation, n = 6-7). 528 529 530 531
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